REGENXBIO Inc. $RGNX is 22NW LP’s 5th Largest Position

22NW LP boosted its position in shares of REGENXBIO Inc. (NASDAQ:RGNX) by 38.1% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 923,679 shares of the biotechnology company’s stock after acquiring an additional 255,000 shares during the period. REGENXBIO accounts for about 5.5% of 22NW LP’s investment portfolio, making the stock its 5th largest position. 22NW LP owned about 1.83% of REGENXBIO worth $7,583,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the company. Pale Fire Capital SE increased its stake in shares of REGENXBIO by 7.7% in the second quarter. Pale Fire Capital SE now owns 27,846 shares of the biotechnology company’s stock worth $229,000 after purchasing an additional 2,000 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in REGENXBIO by 9.1% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 27,756 shares of the biotechnology company’s stock valued at $198,000 after acquiring an additional 2,326 shares during the period. Brooklyn Investment Group raised its holdings in REGENXBIO by 163.7% during the first quarter. Brooklyn Investment Group now owns 5,583 shares of the biotechnology company’s stock valued at $40,000 after acquiring an additional 3,466 shares during the period. Steward Partners Investment Advisory LLC lifted its position in shares of REGENXBIO by 754.1% in the second quarter. Steward Partners Investment Advisory LLC now owns 5,663 shares of the biotechnology company’s stock valued at $46,000 after acquiring an additional 5,000 shares in the last quarter. Finally, Intech Investment Management LLC boosted its stake in shares of REGENXBIO by 26.5% in the second quarter. Intech Investment Management LLC now owns 27,100 shares of the biotechnology company’s stock worth $222,000 after acquiring an additional 5,682 shares during the period. 88.08% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Wall Street Zen upgraded REGENXBIO from a “sell” rating to a “hold” rating in a research report on Monday, November 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of REGENXBIO in a report on Wednesday, October 8th. Chardan Capital reissued a “buy” rating and issued a $52.00 target price on shares of REGENXBIO in a report on Thursday, November 20th. HC Wainwright restated a “buy” rating and set a $34.00 target price on shares of REGENXBIO in a research report on Tuesday, October 7th. Finally, Royal Bank Of Canada lifted their price target on shares of REGENXBIO from $17.00 to $19.00 and gave the company an “outperform” rating in a report on Friday, November 7th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $28.63.

REGENXBIO Stock Performance

Shares of RGNX opened at $13.16 on Monday. The stock has a market capitalization of $666.16 million, a PE ratio of -3.79 and a beta of 1.14. The company’s fifty day moving average is $11.89 and its 200 day moving average is $9.96. REGENXBIO Inc. has a fifty-two week low of $5.03 and a fifty-two week high of $13.93.

REGENXBIO (NASDAQ:RGNX) last issued its quarterly earnings data on Thursday, November 6th. The biotechnology company reported ($1.20) EPS for the quarter, topping analysts’ consensus estimates of ($1.38) by $0.18. REGENXBIO had a negative net margin of 110.29% and a negative return on equity of 78.29%. The business had revenue of $29.73 million during the quarter, compared to analysts’ expectations of $24.41 million. As a group, research analysts forecast that REGENXBIO Inc. will post -4.84 earnings per share for the current year.

Insider Buying and Selling

In other REGENXBIO news, CEO Curran Simpson sold 20,811 shares of the business’s stock in a transaction that occurred on Thursday, October 9th. The stock was sold at an average price of $12.62, for a total transaction of $262,634.82. Following the sale, the chief executive officer directly owned 216,162 shares of the company’s stock, valued at $2,727,964.44. The trade was a 8.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders sold a total of 36,169 shares of company stock valued at $416,598 in the last ninety days. Company insiders own 12.79% of the company’s stock.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.